Interim Results -3-
23 Mars 2010 - 8:01AM
UK Regulatory
commercially availableand the decrease in surplus funds.
Taxation
The Group makes claims each year for research and development tax credits and,
as it is loss-making, elects to surrender these tax credits for a cash rebate.
A tax credit refund of GBP0.6m was received in December 2009.
In the six months ended 31 December 2009 there was a taxation charge of GBP1,000
(31 December 2008: taxation refund of GBP31,000), split GBP16,000 balance of tax
credit refund received over that accrued at 30 June 2009 and US tax charge for
Neuropharm Inc of GBP17,000.
Liquidity, cash and cash equivalents, and money market investments
The net cash used in operating activities was GBP0.9 million (31 December 2008:
GBP3.5 million).
Accrued income and margin deposits at 30 June 2009 were GBPnil (31 December
2008: GBP0.2 million). The decrease is due to the Company's decision to shorten
maturity dates for term deposits to less than one month. There was no hedging
of foreign currency exposure through forward foreign exchange contracts, and
therefore no margin deposits, at the half-year end.
Trade and other receivables at 31 December 2009 were GBP0.1 million (31 December
2008: GBP0.2 million).
Trade and other payables at 31 December 2009 were GBP0.2 million (31 December
2008: GBP1.1 million), primarily due to the retrenchment of spend following the
result of the SOFIA study.
Related party transactions
Transactions between the Company and its subsidiaries, which are related
parties, have been eliminated on consolidation.
There were no other related party transactions during the six months ended 31
December 2009.
Going concern
As disclosed in note 2 to the consolidated financial statements, having made
relevant and appropriate enquiries, including consideration of the Group's
current cash resources and cash flow forecasts, the Board has a reasonable
expectation that, at the time of approving the financial statements, the Group
has adequate resources to continue in operational existence for at least the
next 12 months. Accordingly, the Board continues to adopt the going concern
basis in preparing the financial statements.
Graham E. Yeatman
Chief Financial Officer
22 March 2010
Statement of Directors' responsibilities
We confirm to the best of our knowledge:
a. the condensed set of financial statements has been prepared in accordance
with IAS 34 "Interim Financial Reporting";
b. the interim management report includes a fair review of the information
required by DTR 4.2.7R (indication of important events during the first six
months) except for the omission of principal risks and uncertainties for the
remaining six months of the year; and
c. the interim management report includes a fair review of the information
required by DTR 4.2.8R (disclosure of related party transactions and changes
therein).
By order of the Board
Robert G. Mansfield
Graham E. Yeatman
Chief Executive Officer
Chief Financial Officer
22 March 2010
+---------------------------------------+------+--+----------+---------+---------+
| |
| Consolidated Income Statement |
| Six months ended 31 December 2009 |
| |
+--------------------------------------------------------------------------------+
| |Note | | Six | Six | Year |
| | | | months | months | ended |
| | | | ended | ended | 30 |
| | | | 31 Dec | 31 Dec | June |
| | | | 2009 | 2008 | 2009 |
| | | | GBP'000 | GBP'000 | GBP'000 |
+---------------------------------------+------+--+----------+---------+---------+
| | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| Research and development expenses | | | (67) | (2,262) | (3,472) |
+---------------------------------------+------+--+----------+---------+---------+
| | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| Selling, marketing and distribution | | | - | (246) | (454) |
| costs | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| Other management and administration | | | (1,087) | (1,553) | (3,167) |
| expenses | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| Movement on provision for National | | | - | 45 | 97 |
| Insurance on share options | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| Share option expense | | | (91) | (308) | (450) |
+---------------------------------------+------+--+----------+---------+---------+
| Impairment charge | 6,7 | | - | (189) | (189) |
+---------------------------------------+------+--+----------+---------+---------+
| Total management and administration | | | (1,178) | (2,005) | (3,709) |
| expenses | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| Operating loss | | | (1,245) | (4,513) | (7,635) |
+---------------------------------------+------+--+----------+---------+---------+
| | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| Investment income | | | 32 | 305 | 442 |
+---------------------------------------+------+--+----------+---------+---------+
| Other gains and losses | 4 | | (11) | 719 | 693 |
+---------------------------------------+------+--+----------+---------+---------+
| Loss on ordinary activities before | | | (1,224)) | (3,489) | (6,500) |
| tax | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| Taxation | | | (1) | 31 | 616 |
+---------------------------------------+------+--+----------+---------+---------+
| Loss for the period | | | (1,225) | (3,458) | (5,884) |
+---------------------------------------+------+--+----------+---------+---------+
| | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| Loss per share | | | | | |
+---------------------------------------+------+--+----------+---------+---------+
| Basic and diluted | 5 | | (3.9)p | (11.0)p | (18.7)p |
+---------------------------------------+------+--+----------+---------+---------+
All results derive from continuing operations.
+----------------+---------+---------+---------+-------------+--------------+----------+---------+
| Consolidated Statement of Changes in Equity |
| Six months ended 31 December 2009 |
| |
+------------------------------------------------------------------------------------------------+
| | Called | Share | | Foreign | Share-based | Retained | Total |
| | up | premium | Other | currency | compensation | loss | GBP'000 |
| | share | account | reserve | translation | GBP'000 | GBP'000 | |
| | capital | GBP'000 | GBP'000 | reserve | | | |
| | GBP'000 | | | GBP'000 | | | |
+----------------+---------+---------+---------+-------------+--------------+----------+---------+
| | | | | | | | |
+----------------+---------+---------+---------+-------------+--------------+----------+---------+
Neuropharm (LSE:NPH)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Neuropharm (LSE:NPH)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
Real-Time news about Neuropharm (London Stock Exchange): 0 recent articles
Plus d'articles sur Neuropharm